Abstracts | 39 patients with schizophrenia or bipolar disorder. Quality of life (QoL) is the general feelings of well-being of individuals. In this study, we measured the QoL in patients with schizophrenia or bipolar disorder who were receiving LAI treatment. Methods: 434 patients with schizophrenia and 42 patients with bipolar disorder received LAI treatment for at least 6 months regularly at Taipei City Psychiatric Center were administered with Brief World Health Organization's Quality of Life (WHOQoL), Chinese Health Questionnaire (CHQ), Subjective Well-being under Neuroleptics (SWN) and Social Performance scale (PSP) in a cross-sectional interview. Results: The duration of LAI treatment was 8.6 ± 8.9 years for schizophrenia and 5.5 ± 7.5 years for bipolar disorder, with total scores of WHOQoL 50.4 ± 8.9 and 52.1 ± 8.9, respectively (Norm: 56.1 in Taiwan). There was no difference in WHOQOL, CHQ between the two groups, while the bipolar patients had slightly higher SWN (81.8 ± vs 13.278.1 ± 12.2, P= 0.060) and significant PSP scores (74.6 ± 5.8 vs 71.0 ± 5.9, P<0.001). The Frequency of hospitalization (times/year) were significantly decreased after LAI treatment in schizophrenia (0.26 ± 0.42 to 0.09 ± 0.24) and bipolar disorder (0.56 ± 0.67 to 0.15 ± 0.39). Conclusions: LAI treatment can efficaciously prevent the relapse of psychotic or mood episodes in patients with poor adherence to medications. Patients with bipolar disorders reported a slightly higher satisfaction, in terms of SWN and PSP, but not QoL and CHQ, than patients with schizophrenia. These results suggest that patients with schizophrenia or bipolar disorder can have an acceptable level of QoL when they are under a regular adherence to medications.
Abstract
Objective: Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant schizophrenia. Clozapine is underutilized in the management of treatmentresistant schizophrenia. To understand contributing factors, we analyzed the time course and causes of clozapine discontinuations that occurred over a 20-year period in a clinical setting. Method: The reasons for discontinuation and duration of clozapine treatment from a retrospective database of 138 patients with schizophrenia who had prescribed clozapine at least a month were reviewed, with the motives for discontinuation coded. The causes for termination were analyzed. Results: Over two-thirds of the patient had ceased clozapine. The two most common causes for discontinuation were side-effects (51%), and own decision (29%). Somnolence accounted for 31% of all side-effects induced discontinuations. Hematological problems accounted for 21% of side-effect. The Maximal treatment dose of clozapine was higher in continuation group (411.31mg) than in discontinuation group (340.89mg). The CGI-S score when prescribing clozapine last was higher in discontinuation group than in continuous group. The patients who took atypical antipsychotics before clozapine tended to cease clozapine because of side-effects than who took typical agent. Conclusions: Future studies should seek various methods to relieve side-effects of clozapine. Prospective researches using more objective tools are needed to clarify the reason for clozapine discontinuation. Key words: schizophrenia, clozapine, antipsychotics, treatment discontinuation, side-effect
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Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study.
and index date were included. Antipsychotic exposure was categorized by type, duration, and daily dose, and the association between antipsychotic exposure and cataract development was assessed using a conditional logistic regression analysis. Results: We found that the severity of physical comorbidities, concurrent antidepressant use, and comorbidity with glaucoma or other retinal disorders were associated with an increased risk for cataract development. Alternatively, we did not find significant associations between continuous use of clozapine, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, amisulpride, zotepine or aripiprazole and risk of cataract development in SZ patients. Conclusions: We did not detect any association between atypical antipsychotic use and risk of cataract development in SZ patients. However, given that SZ patients often have risk factors for developing cataract such as diabetes mellitus, hypertension, and metabolic syndrome, mental health care providers should ensure that patients receive regular ocular evaluations. Future studies with longitudinal ocular evaluations in patients using atypical antipsychotics are warranted to confirm our findings.
